Eleven Biotherapeutics Secures $20 Million and Expands Series A Financing
Eleven Biotherapeutics Secures $20 Million and Expands Series A Financing
Company to Advance its lead Drug Candidate, EBI-005, into Clinic Development for Dry Eye Disease
US Scientists Who Mean Business
Vaccine Could Stop Nicotine from Reaching the Brain
Vaccine Could Stop Nicotine from Reaching the Brain
The new antismoking technique uses nanoparticles to trigger an immune response.
By Conor Myhrvold
Seahorse Announces the XF Glycolysis Stress Test Kit
Seahorse Announces the XF Glycolysis Stress Test Kit
BILLERICA, Mass., April 25, 2012 -- /PRNewswire/ -- Seahorse Bioscience, the leader in cellular bioenergetic measurements, announced the launch of its newest stress test kit at the American Association of Cancer Research (AACR) Annual Meeting 2012. The XF Glycolysis Stress Test Kit is the first Standard for measuring glycolytic capacity in cells.
Dr. Noubar Afeyan, Flagship's Managing Partner and CEO, speaking on Investor Panel at BIO World Congress on Industrial Biotechnology & Bioprocessing
Dr. Noubar Afeyan, Flagship's Managing Partner and CEO, speaking on Investor Panel at BIO World Congress on Industrial Biotechnology & Bioprocessing
Click here to see announcement.
Michigan Growth Capital Symposium Unveils Flagship Ventures' Noubar Afeyan as Keynote Speaker
Michigan Growth Capital Symposium Unveils Flagship Ventures' Noubar Afeyan as Keynote Speaker
Society for Biological Engineering Announces Inaugural Winners of Wang Award
Society for Biological Engineering Announces Inaugural Winners of Wang Award
NEW YORK – The Society for Biological Engineering (SBE) of the American Institute of Chemical Engineers (AIChE) has announced the inaugural winners of the D. I. C. Wang Award for Excellence in Biochemical Engineering. The inaugural recipients of the award, established in appreciation of Professor Daniel I.C. Wang of the Massachusetts Institute of Technology (MIT), are Noubar Afeyan of Flagship Ventures and James Swartz of Stanford University.
Shire Adds new Technology Platform and Phase 2 Product Candidate to its Regenerative Medicine Business
Shire Adds new Technology Platform and Phase 2 Product Candidate to its Regenerative Medicine Business
Tangent Medical Submits FDA 510(k) for NovaCath™ Secure IV Catheter System
Tangent Medical Submits FDA 510(k) for NovaCath™ Secure IV Catheter System
First Targeted Nanomedicine to Enter Human Clinical Studies is a Paradigm Shift in Anti-tumor Efficacy and Safety in Cancer Patients
First Targeted Nanomedicine to Enter Human Clinical Studies is a Paradigm Shift in Anti-tumor Efficacy and Safety in Cancer Patients
BOSTON, MA—A team of scientists, engineers and physicians from Brigham and Women’s Hospital (BWH), Dana-Farber Cancer Institute (DFCI), Harvard Medical School (HMS), Massachusetts Institute of Technology (MIT), BIND Biosciences, Translational Genomics Research Institute (TGen), Wayne State University Karmanos Cancer Institute, and Weill Cornell Medical College have found promising effects of a first-in-class targeted cancer drug called BIND-014 in treating solid tumors.


